<DOC>
	<DOCNO>NCT00180518</DOCNO>
	<brief_summary>1 . To evaluate safety efficacy over-the-wire ( OTW ) ACCULINK ( tm ) System patient deem either high risk unsuitable carotid endarterectomy ( CEA ) 2 . To evaluate efficacy OTW ACCUNET System patient deem either high risk unsuitable carotid endarterectomy ( CEA ) . 3 . To demonstrate equivalence safety performance RX ACCULINK Carotid Stent System RX ACCUNET Embolic Protection System correspond OTW device .</brief_summary>
	<brief_title>ACCULINK Revascularization Carotids High Risk Patients `` The ARCHeR Trial ''</brief_title>
	<detailed_description>The purpose study demonstrate equivalence safety performance RX ACCUNET use RX ACCULINK , ACCULINK ACCUNET device , treatment high risk surgical patient patient anatomical risk require treatment carotid artery disease . Patients ARCHeR RX follow index procedure one , six 12 month . Equivalence safety demonstrate compare 30-day rate DSMI ARCHeR Amendment 2 ARCHeR RX . Secondary analysis perform rate ipsilateral stroke 31 day 12 month , target lesion revascularization six 12 month , acute device success RX ACCULINK RX ACCUNET Systems , clinical success , access site complication require treatment . Additionally , stented segment evaluate carotid duplex ultrasound six 12 month . Serious adverse event ( SAE ) death ipsilateral stroke occur anytime follow-up period identify report , adjudicate indicate .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Carotid Artery Diseases</mesh_term>
	<criteria>1 . Patient age &gt; =18 . 2 . Symptomatic patient : Transient ischemic attack ( TIA ) , amaurosis fugax , minor/nondisabling stroke ( hemisphere supply target vessel ) within 180 day enrollment ; asymptomatic patient : meet angiographic clinical inclusion criterion . 3 . Patient childbearing potential negative pregnancy test within 30 day study procedure . 4 . Patient legally authorize representative , patient 's physician , agree patient return require clinical contact follow study enrollment . 5 . Patient legally authorize representative inform nature study , provide write informed consent , approve appropriate Institutional Review Board ( IRB ) /Medical Ethics Committee ( MEC ) respective clinical site . ( Sample consent Appendix A2 ) . 6 . Patient must meet two criterion list ae OR one criterion list fq : 1 . Knowledge two proximal major diseased coronary artery &gt; =70 % stenosis , revascularized ; 2 . Unstable angina define rest angina ECG change ; 3 . MI within previous 30 day current need carotid artery revascularization 4 . Concurrent requirement aortocoronary bypass cardiac valve surgery within 30 day ; 5 . Contralateral occlusion ICA ; 6 . Currently list major organ transplantation ( i.e . heart , lung , liver , kidney ) evaluate ; 7 . Ejection fraction &lt; 30 % New York Heart Association ( NYHA ) Functional Class III high ; 8 . FEV1 &lt; 30 % ( Predicted ) ; 9 . Dialysisdependent renal failure ; 10 . Uncontrolled diabetes define fast glucose &gt; 400 mg/dl ketone &gt; 2+ ; 11 . Restenosis previous CEA ( define &gt; =50 % angiography symptomatic patient &gt; =80 % angiography asymptomatic patient ) ; 12 . Patient status/post radiation treatment neck ; 13 . Patient status/post radical neck surgery ; 14 . Surgically inaccessible lesion ( e.g . lesion level C2 clavicle , lesion obstruct tumor neck ) ; 15 . Spinal immobility inability flex neck beyond neutral kyphotic deformity ; 16 . Presence tracheostomy stoma ; 17 . Contralateral laryngeal nerve paralysis . Anatomic Inclusion Criteria NOTE : Angiographic measurement must make utilize either online quantitative carotid angiography ( QCA ) electronic caliper magnification correction . 1 . Patient discrete lesion locate ICA ( without involvement contiguous CCA ) . 2 . Carotid stenosis must &gt; = 50 % angiography ( symptomatic patient ) &gt; = 80 % angiography ( asymptomatic patient ) . 3 . Target ICA vessel reference diameter must &gt; =4.0 mm = &lt; 9.0 mm angiography . NOTE : Patients bilateral carotid stenosis eligible . Management nonstudy stenosis may do accordance local Principal Investigator recommendation . Treatment nonstudy artery must take place either &gt; 30 day &gt; 30 day study procedure complete . Specific ACCUNET System 4 . Expected ability deliver ACCUNET System distal lesion ( absence excessive tortuosity ) available straight mildly angulate segment &gt; = 4 cm , angiography , distal ICA ( prior petrous portion vessel ) place embolic protection device . 5 . The diameter straight mildly angulate segment , distal ICA prior petrous portion vessel , must &gt; = 3.25 mm = &lt; 7.5 mm angiography . Candidates ineligible enrollment study one follow condition apply : 1 . Patient evolve stroke . 2 . Patient history intolerance allergic reaction study medication material , include heparin , aspirin , baby aspirin , nitinol , xray contrast . 3 . Patient history intolerance allergic reaction ticlopidine clopidogrel . 4 . Patient active bleeding diathesis coagulopathy refuse blood transfusion . 5 . Patient history major ipsilateral stroke likely confound study endpoint . 6 . Patient severe dementia . 7 . Patient history spontaneous intracranial hemorrhage within past 12 month . 8 . Patient recent ( &lt; 7 day ) stroke sufficient size ( CT MRI ) place risk hemorrhagic conversion procedure . 9 . Patient hemorrhagic transformation ischemic stroke within past 60 day . 10 . Patient Hgb &lt; 8 gm/dl ( unless dialysis ) , platelet count &lt; 50,000 , uncorrected INR &gt; 1.5 , heparinassociated thrombocytopenia . 11 . Patient condition precludes proper angiographic assessment make percutaneous arterial access unsafe ( e.g . morbid obesity , sustain SBP &gt; 180 mm Hg. ) . 12 . Patient neurologic illness within past two year characterize fleeting fix neurologic deficit distinguish TIA stroke ( e.g . partial secondarily generalize seizure ; complicate classic migraine ; tumor spaceoccupying brain lesion ; subdural hematoma , cerebral contusion posttraumatic lesion ; intracranial infection ; demyelinate disease ; moderate severe dementia ; intracranial hemorrhage ) . 13 . Patient actively participate another drug device trial ( IND IDE ) complete require protocol followup period . Patients may enrol ARCHeR clinical trial may participate clinical trial ARCHeR followup period . 14 . Patient patient 's legally authorize representative unable understand cooperate study procedure provide inform consent . 15 . Patient life expectancy less two year . 16 . Patient vertebrobasilar insufficiency symptom , without clearly identifiable symptom referable targeted carotid artery 17 . Knowledge cardiac source emboli ( e.g . leave ventricular aneurysm , atrial fibrillation , intracardiac filling defect , cardiomyopathy , aortic mitral prosthetic heart valve , cardioversion atrial fibrillation within 30 day prior intervention , calcific aortic stenosis , endocarditis , mitral stenosis , atrial septal defect ( ASD ) , atrial septal aneurysm , leave atrial myxoma ) . 18 . Patient recent GI bleed would interfere antiplatelet therapy . Anatomic Exclusions 1 . Severe vascular tortuosity anatomy would preclude safe introduction guide catheter , guide sheath , embolic protection system , stent system . 2 . Presence previously place intravascular stent intravascular graft ipsilateral distribution . ( Patch graft exclusion criterion . ) 3 . Presence extensive diffuse atherosclerotic disease involve aortic arch proximal common carotid artery would preclude safe introduction guide catheter guide sheath . 4 . An intraluminal filling defect ( defined endoluminal lucency surround contrast , see multiple angiographic projection , absence angiographic evidence calcification ) associate ulcerated target lesion 5 . Other abnormal angiographic finding : ipsilateral intracranial extracranial arterial stenosis great severity lesion treat , cerebral aneurysm &gt; = 5 mm , AVM ( arteriovenous malformation ) cerebral vasculature , AV fistula , confound intracranial lesion . 6 . Bilateral carotid stenosis intervention plan within 30day ARCHeR periprocedure period . 7 . Occlusion [ Thrombolysis In Myocardial Infarction Trial ( TIMI 0 ) ] `` string sign '' &gt; 1 cm ipsilateral common internal carotid artery .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Carotid artery disease</keyword>
	<keyword>High risk</keyword>
	<keyword>High surgical risk</keyword>
</DOC>